Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | CEND-1 |
Trade Name | |
Synonyms | CEND1|CEND 1 |
Drug Descriptions |
CEND-1 is a peptide that is targeted to tumors via interaction with alpha-integrins and potentially increases the delivery of other antitumor agents via interaction with neuropilin-1 (Annals of Oncology 31 (2020): S941). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C103858 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CEND-1 | CEND-1 | 0 | 0 |
CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | CEND-1 Fluorouracil Irinotecan Leucovorin Oxaliplatin | 0 | 1 |
CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab | CEND-1 Fluorouracil Irinotecan Leucovorin Oxaliplatin Panitumumab | 0 | 1 |
CEND-1 + Gemcitabine + Nab-paclitaxel | CEND-1 Gemcitabine Nab-paclitaxel | 0 | 1 |